Pharmacoeconomic Aspects of Using New-Generation Drugs of the PCSK-9 Inhibitor Class and Those Utilizing the Effect of Ribonucleic Acid Interference in the Treatment of Patients With Hypercholesterolemia
{{output}}
Aim Clinical and economic analysis of the feasibility of using new-generation drugs of the PCSK-9 inhibitor class (alirocumab and evolocumab) and the drugs that utilize in their action the effect of ribonucleic acid interference (inclisiran) in the treatment o... ...
